Predictive Ihc Microscope Scoring by Tayade Vishal (3 results)

- Softcover
Seller: BargainBookStores, Grand Rapids, MI, U.S.A.BargainBookStores
Contact seller5-star sellerCondition: New
£ 32.25
Free ShippingShips within U.S.A.Quantity: 5 available
Paperback or Softback. Condition: New. Predictive IHC at the Microscope: Scoring the Markers That Choose the Drug. Book.

- Softcover
Seller: California Books, Miami, FL, U.S.A.California Books
Contact seller5-star sellerCondition: New
£ 33.54
£ 2.27 shippingShips within U.S.A.Quantity: Over 20 available
Condition: New.

Language: English
Published by Amazon Digital Services LLC - Kdp Sep 2026, 2026
- Softcover
Seller: AHA-BUCH GmbH, Einbeck, GermanyAHA-BUCH GmbH
Contact seller5-star sellerCondition: New
£ 57.93
£ 29.14 shippingShips from Germany to U.S.A.Quantity: 2 available
Taschenbuch. Condition: Neu. Neuware - Immunohistochemistry no longer only names a tumour - increasingly, it chooses the drug. A membrane score gates an antibody-drug conjugate; a percentage of stained nuclei opens or closes a line of therapy; a pattern of nuclear loss unlocks immunotherapy across the body.Yet the threshold that decides treatment is not a fact about the tumour. It is a decision rule tied to a particular trial, a particular drug, and a particular assay. For every predictive marker, this pan-tumour guide sets out what to score, where the cutoff came from, how reproducibly it can be read, and how to report it in language the oncologist can act on.Markers covered: PD-L1 - HER2 and HER2-low/ultralow - MMR/MSI - ER, PR and Ki-67 - Trop-2 - Nectin-4 - FRa - Claudin 18.2 - HER3 - B7-H3 - quantitative and AI-assisted scoring.Inside this edition: fifteen focused chapters across four parts; the trial-validated cutoff behind every marker; reproducibility and the faint-end problem, marker by marker; pitfalls at the bench, controls, and external quality assurance; assay, clone and platform specifics throughout; and synoptic reporting templates.Written for practising pathologists, trainees, and tumour-board participants.Expression is not eligibility.…